Tag: $Abbvie Inc

AbbVie forecast 2026 profit above Wall Street estimates on Wednesday after posting a fourth-quarter results beat, fueled by strong ​demand for newer immunology drugs Skyrizi and Rinvoq and a smaller-than-expected ‌decline in sales of its older medicine Humira.

AbbVie (ABBV +3.15%) gave investors reason to cheer, reporting higher earnings than expected for a fifth straight quarter and raising its financial forecasts for the year.

Dec 6 (Reuters) – AbbVie said on Wednesday it would buy Cerevel Therapeutics , a developer of drugs for neurological conditions, for about $8.7 billion in a bid to replace revenue as its arthritis drug Humira faces a raft of new competition.

Nov 30 (Reuters) – AbbVie said on Thursday it will buy drugmaker ImmunoGen for $10.1 billion, adding a promising drug for ovarian cancer to its portfolio of oncology treatments.

The U.S. Food and Drug Administration (FDA) greenlighted Roche Holding AG’s experimental therapy to treat a type of advanced blood cancer, nearly a month after the approval of a rival therapy from AbbVie Inc.